Saridegib
| CAS No. | 1037210-93-7 | Cat. No. | BCP25392 |
| Name | Saridegib | ||
| Synonyms | IPI 926; IPI-926; IPI926;Patidegip; | ||
| Formula | C29H48N2O3S | M. Wt | 504.77 |
| Description | Saridegib, also known as IPI-926, is an orally bioavailable, cyclopamine-derived (for structure comparison see Fig 1) inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, Hedgehog pathway inhibitor IPI-926 binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Smoothened/Smo | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.